Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will announce its unaudited interim results for the six months ended 30 June
Omega Diagnostics Gp (AIM:ODX) Directorate Change
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces that Chris Lea, Group Finance Director of the Company, will be stepping down as
Abingdon Health PLC (AIM:ABDX) Salistick™ to be launched in Tesco
Salistick™, the first ever saliva pregnancy test, to be launched in Tesco
Yourgene Health PLC (AIM:YGEN) Rule 2.7 Announcement
RECOMMENDED CASH OFFER by Novacyt UK Holdings Limited (a wholly-owned subsidiary of Novacyt S.A.) for Yourgene Health plc to be effected by means of a Scheme of Arrangement under Part
Avacta Group PLC (AIM:AVCT) Completion of Fifth Dose Escalation in AVA6000
Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
Abingdon Health PLC (AIM:ABDX) Launch of Salistick™ saliva pregnancy test
Superdrug to sell Salistick™, the first ever saliva pregnancy test, initially in 400 stores and online Salistick™ also to launch on the Abingdon Simply Test website
Avacta Group PLC (AIM:AVCT) Statement regarding market speculation
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, notes the recent market speculation regarding possible fundraising.
Avacta Group PLC (AIM:AVCT) AGM and Shareholder Event Detailed Agenda
Avacta Annual General Meeting and Shareholder Event Detailed Agenda
Avacta Group PLC – Second Milestone in AffyXell Joint Venture
Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake
Avacta Group PLC – Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December
Novacyt S.A. Final Results, Full year revenue and EBITDA
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Avacta Group PLC has announced that the first patient has been dosed in the US in the AVA6000 Phase 1 trial.
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial